Percutaneous pulmonary valve implantation: two-centre experience with more than 100 patients

Abstract

Dysfunction of valved conduits in the right ventricular outflow tract (RVOT) limits durability and enforces repeated surgical interventions. We report on our combined two-centre experience with percutaneous pulmonary valve implantation (PPVI). One hundred and two patients with RVOT dysfunction [median weight: 63 kg (54.2–75.9 kg), median age: 21.5 years (16.2–30.1 years), diagnoses: TOF/PA 61, TAC 14, TGA 9, other 10, AoS post-Ross-OP 8] were scheduled for PPVI since December 2006. Percutaneous pulmonary valve implantation was performed in all patients. Pre-stenting of the RVOT was done in 97 patients (95%). The median peak systolic RVOT gradient decreased from 37 mmHg (29–46 mmHg) to 14 mmHg (9–17 mmHg, P < 0.001) and the ratio RV pressure/AoP decreased from 62% (53–76%) to 36% (30–42%, P < 0.0001). The median end-diastolic RV-volume index (MRI) decreased from 106 mL/m² (93–133 mL/m²) to 90 mL/m² (71–108 mL/m², P = 0.001). Pulmonary regurgitation was significantly reduced in all patients. One patient died due to compression of the left coronary artery. The incidence of stent fractures was 5 of 102 (5%). During follow-up [median: 352 days (99–390 days)] one percutaneous valve had to be removed surgically 6 months after implantation due to bacterial endocarditis. In 8 of 102 patients, a repeated dilatation of the valve was done due to a significant residual systolic pressure gradient, which resulted in a valve-in-valve procedure in four. This study shows that PPVI is feasible and it improves the haemodynamics in a selected patient collective. Apart from one coronary compression, the rate of complications at short-term follow-up was low. Percutaneous pulmonary valve implantation can be performed by experienced interventionalists with similar results as originally published. The intervention is technically challenging and longer clinical follow-up is needed.